Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Respiratory Restriction Leaded by Conventional or Minimally Invasive Sugical Repair of Oesophageal Atresia in Children (RestriMIS2)

12 novembre 2026 mis à jour par: University Hospital, Angers

Assessment of Respiratory Restriction Caused by Chest Wall Abnormalities Following Conventional or Minimal Invasive Surgical Repair of Type III Esophageal Atresia in School Age Children

Children born with esophageal atresia need surgery shortly after birth. For many years, the standard operation was a thoracotomy, an opening in the chest that can sometimes lead to changes in the shape of the chest wall. Although these changes are visible on X rays, doctors still do not fully understand how much they affect breathing later in childhood. A newer, less invasive technique called thoracoscopy uses small incisions and appears to cause fewer chest deformities, but its impact on lung function has not yet been clearly established.

This study aims to compare the breathing capacity of children aged 6 to 9 who were operated on using either thoracotomy or thoracoscopy. The main question is whether one group is more likely to develop restrictive lung syndrome, a condition in which the lungs cannot expand normally. To answer this, the study relies on lung function tests and chest X rays performed during routine follow up visits.

Beyond this primary goal, the study also examines other possible breathing problems, the presence of chest wall abnormalities, and factors that might influence lung health, such as nutrition, physical activity, associated malformations, and overall quality of life.

A total of at least 360 children across France will participate. They are identified through national registries and invited during scheduled follow up consultations.

Aperçu de l'étude

Type d'étude

Observationnel

Inscription (Estimé)

360

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Amiens, France, 80054
        • CHU Amiens, Département de Pédiatrie, centre d'activité "chirurgie pédiatrique viscérale"
        • Contact:
        • Chercheur principal:
          • Philippe BUISSON, MD
      • Angers, France, 49933
        • CHU Angers, Service Urgences, Médecine, Psychiatrie et Chirurgie Pédiatriques
        • Contact:
        • Chercheur principal:
          • francoise SCHMITT, MD
      • Clermont-Ferrand, France, 63003
        • CHU Clermont-Ferrand, Service de pédiatrie générale et multidisciplinaire
        • Contact:
        • Chercheur principal:
          • Carole EGRON, MD
      • Dijon, France, 21000
        • CHU Dijon, Service de chirurgie pédiatrique
        • Contact:
        • Chercheur principal:
          • Michel FRANCOIS, MD
      • Grenoble, France, 38700
        • CHU Grenoble, Service de chirurgie pédiatrique
        • Contact:
        • Chercheur principal:
          • Pierre-Yves RABATTU, MD
      • Le Kremlin-Bicêtre, France, 94275
        • Hôpital Bicêtre, AP-HP, Chirurgie Viscérale Pédiatrique
        • Contact:
        • Chercheur principal:
          • Khadidja KHADIR, MD
      • Lyon, France, 69677
        • Hospices Civils de Lyon, Service d'Hepato-Gastroentérologie et Nutrition Pédiatrique
        • Contact:
        • Chercheur principal:
          • Nicolas CARON, MD
      • Nantes, France, 44093
        • CHU Nantes, Hôpital Mère-Enfant, Service de Chirurgie Infantile
        • Contact:
        • Chercheur principal:
          • Audrey GUINOT, MD
      • Paris, France, 75015
        • Hôpital Necker Enfants Malades, AP-HP, Service de Pneumologie et Allergologie Pédiatriques
        • Contact:
        • Chercheur principal:
          • Rola ABOU TAAM, MD
      • Strasbourg, France, 67098
      • Toulouse, France, 31059
        • CHU Toulouse, Service de Chirurgie Viscérale Pédiatrique
        • Contact:
        • Chercheur principal:
          • Aurelie LE MANDAT, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

6 ans à 10 ans (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Eligible patients in both groups are mainly identified through the national esophageal atresia registry (RENATO, CRACMO, CHU Lille).

La description

For thoracoscopy group:

Inclusion Criteria:

  • Child operated on by thoracoscopy for type 3 AO (excluding long gap) according to Ladd's classification
  • Child aged 6 to 10 years old
  • Consent from parents (or legal guardians) and the child's agreement to participate in the study

Exclusion Criteria:

  • Heart or lung malformation diagnosed at birth and requiring surgery
  • Conversion from thoracoscopy to thoracotomy during the procedure
  • Child who has had more than one thoracic surgery (reoperation for AO, other reasons for thoracic surgery including heart surgery)
  • For Thoracotomy group*:

Inclusion Criteria :

--Child operated on by thoracotomy for type 3 AO (excluding long gap) according to the Ladd classification

  • Child aged 6 to 10 years old
  • Consent from parents (or legal guardians) and the child's agreement to participate in the study

Exclusion Criteria:

  • Heart or lung malformation diagnosed at birth and requiring surgery
  • Child who has had more than one thoracic surgery (reoperation for AO, other reason for thoracic surgery including heart surgery)
  • Child operated on for type 3 AO via thoracotomy (excluding long gap) according to Ladd's classification

For each patient who underwent thoracoscopic surgery included in the study, two patients who had thoracotomy, matched according to known or suspected confounding factors for restrictive syndromes from the RestriMIS1 (NCT04136795) study**, will be included.

*It's possible that some children had multiple consecutive surgeries. In those cases, if one of the procedures was a thoracotomy, the children will be classified in the thoracotomy group (the more major surgery).

**Prematurity, birth weight, presence of tracheomalacia, and GERD during the neonatal period (clinically and/or on additional tests)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
thoracoscopy group

minimally invasive surgical approach

thoracotomy arm

conventionnal surgical approach

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
to assess the presence of a restrictive lung syndrome in patients with type 3 esophageal atresia (EA) depending on the type of surgical approach used (conventional or minimally invasive).
Délai: Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)

Rate of restrictive syndrome according to the type of surgical approach (conventional or minimally invasive), defined by spirometry data: FEV1/FVC > -1.64 Z-score and FVC < -1.64 Z-score, according to the ATS/ERS-GLI (American Thoracic Society & European Respiratory Society - Global Lung Initiative) recommendations published in 2012 (Quanjer) and reviewed en 2022.

Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
to evaluate the importance of restrictive syndrome
Délai: importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)

The importance of restrictive syndrome is classified into 3 levels: mild restrictive syndrome [-1.64 > z-score ≥ -2.5], moderate [-2.5 > z-score ≥ -4.0], or severe [-4.0 > z-score]).

importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)
Looking for other respiratory parameters
Délai: the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation

Other respiratory changes are examined by measuring other respiratory parameters (forced vital capacity, FEF 25-75, Tiffeneau ratio, reversibility), which help highlight obstructive or mixed syndromes (FEV1/FVC < -1.64 and FVC < -1.64 z-score) when present

the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation
to assess the link between chest skeletal abnormalities found on chest X-rays and lung impact
Délai: until spirometry is completed, within a maximum period of 2 years

The following factors are considered when estimating the risk of association with or without a restrictive syndrome (history data like prematurity or types of malformations associated with AO III, surgical and medical care data in the neonatal period and childhood, growth data at one year and at 6-10 years), lung care, physical activity, the PedsQL score (for children aged 6 to 10), and responses to the EA-QoL questionnaire (for children aged 8 to 10).

until spirometry is completed, within a maximum period of 2 years
rate of postoperative complications and any necessary reoperations
Délai: up to 2 years after the multidisciplinary consultation

The rate of postoperative complications is assessed by type of surgery as well as any necessary follow-up surgeries.

up to 2 years after the multidisciplinary consultation
Respiratory-related quality of life during childhood
Délai: up to 2 years after the multidisciplinary consultation

It will be estimated through both need for lung care, physical activity, PedsQL score (for children aged 6 to 10), and EA-QoL questionnaire (for children aged 8 to 10).

up to 2 years after the multidisciplinary consultation
to assess the existence of a cause-and-effect link between the restrictive syndrome and the surgical technique used
Délai: through study completion, within a maximum of 24 months

The acceptability of the existence of a causal link is assessed using sensitivity analysis, which estimates how robust the results are while taking into account missing data and different clinical scenarios (including a per-protocol analysis in addition to the intention-to-treat analysis).

through study completion, within a maximum of 24 months
to assess the mortality rate
Délai: through study completion, an average 7 years

The death rate for each surgery group will be described based on the follow-up in the study, that is, the date of the surgery (combined data for all patients in the registry).

through study completion, an average 7 years
Looking for lung volumes variations
Délai: the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation

Lung volume variations will be measured by dynamic respiratory MRI data

the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

2 décembre 2026

Achèvement primaire (Estimé)

2 décembre 2032

Achèvement de l'étude (Estimé)

2 décembre 2032

Dates d'inscription aux études

Première soumission

22 septembre 2026

Première soumission répondant aux critères de contrôle qualité

12 novembre 2026

Première publication (Réel)

17 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner